Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis

AbbVie M15-340

Condition: Rheumatology
Phase: I
Clinicaltrials.gov ID: NCT03725007

What is the goal of the study?

This is a drug trial of Upadacitinib. The goal is to evaluate the pharmacokinetics, safety, and tolerability of multiple doses of upadacitinib in pediatric subjects with pcJIA. to evaluate the platability of upadacitinib oral solution in pediatric subjects. And to evaluate the long-term safety and tolerability of multiple doses of upadacitinib in pediatric subjects with pcJIA.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Kabita Nanda
Study Team Member: Michelle Geiszler, Michelle.Geiszler@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.